Substance Spotlight: psychedelics-empathogens — the post-Lykos redesign

When the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy application in 2024, it wasn’t really a verdict on MDMA. It was a verdict on the way the entire psychedelic field had been running its Phase 3 trials.

The advisory committee’s specific concerns were technical: functional unblinding (participants and therapists could almost always tell who got the active drug), unstandardized psychotherapy protocols (the therapy half of the intervention varied study to study and even therapist to therapist), and durability (the question of whether benefits held up at 12 and 24 months). Each of those is fixable. Together they were enough to send a category-defining application back for what amounts to a generational revision.

This Spotlight isn’t about the rejection. It’s about what the field is doing now — eighteen months later, in the middle of a regulatory environment that has shifted dramatically in their favor.

Lens: science (the technical fixes)

Developers are running blinded studies with active comparators (low-dose MDMA, niacin, low-dose psilocybin) instead of inert placebo, on the theory that an active comparator at least confuses the unblinding signal. Therapy protocols are being formally manualized — not just described in supplementary materials — and therapists are being audited against the manual mid-trial. Durability is being engineered into the primary endpoint, with 26-week and 52-week follow-ups becoming the new minimum, not the bonus.

Compass Pathways’ Phase 3 psilocybin readout hit its primary endpoint in 2025 but did not impress investors — for reasons that have to do with the same concerns that grounded Lykos. The second Phase 3 cleared more recently, on stronger ground. DemeRx’s noribogaine for alcohol use disorder is taking yet a different path — separating the metabolite from the parent compound to sidestep both the cardiac risk profile and the heavy psychoactive experience that complicates blinding.

Lens: treatment (what reaches patients, when)

The April 18, 2026 Executive Order on Accelerating Medical Treatments for Serious Mental Illness directs the FDA to expedite review of breakthrough-designated psychedelic compounds, allocates $50 million for ibogaine studies, and opens a Right to Try pathway for treatment-resistant patients. The EO doesn’t override the trial-design problems Lykos exposed. It accelerates the calendar around them.

That creates a tension the field is going to have to navigate publicly. A faster review timeline in the absence of trial-design improvements would mean approving therapies whose efficacy data still has the same blind spots Lykos got rejected for. A faster timeline alongside the trial-design improvements is the right outcome. The question for 2026 is whether sponsors invest the time to do the harder methodology work even when the regulatory door is more open than it has been in fifty years.

Lens: policy (what’s at stake)

There are two failure modes worth naming. The first is that approvals come with such weak evidence that insurers refuse coverage and the therapies become available only at cash-pay clinics — replicating the Spravato access pattern that has frustrated psychiatry for the last six years. The second is that the patient population most likely to benefit — people with treatment-resistant depression, PTSD, severe alcohol use disorder, or treatment-resistant SUD — accesses the molecules through unregulated underground providers because the supervised pathway is too slow. The Right to Try expansion partially mitigates this, but Right to Try has historically been used by a few hundred patients per year. The need is in the millions.

Recent developments at a glance

• April 18, 2026 — EO directs FDA to fast-track psychedelic Breakthrough Therapy reviews; $50M allocated for ibogaine; Right to Try expanded.
• April 24, 2026 — FDA priority vouchers issued to three psychedelic developers (psilocybin TRD, psilocybin MDD, methylone PTSD).
• April 22, 2026 — DemeRx IND accepted for DMX-1001 (oral noribogaine) for alcohol use disorder.
• May 6, 2026 — A STAT op-ed by a researcher in psychedelic-assisted therapy argues the EO is the right move — and that the field is not ready.

Where the field disagrees

Two camps have surfaced. One holds that institutional caution has cost lives and the EO finally cuts through it. The other holds that approving therapies on the same evidence base that produced Lykos’s rejection will damage the field’s long-term credibility and slow downstream insurance coverage. Both groups share a goal — get effective therapies to patients. They disagree about which timeline serves that goal.

The other holds that approving therapies on the same evidence base that produced Lykos’s rejection will damage the field’s long-term credibility and slow downstream insurance coverage.

Resources

If you are a patient considering psychedelic-assisted therapy: ask your physician for a referral to a clinical trial through ClinicalTrials.gov. The Right to Try pathway exists, but it is best navigated with a physician on your side.

If you are a clinician: your local Psychedelic Medicine Society chapter is likely to have updated training pathways; the post-Lykos curriculum updates are real.

For broader navigation, Rize Recovery is in private beta with an Arizona launch focus.

If you are in immediate crisis, call 988.